See more : China Union Holdings Ltd. (000036.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Levitee Labs Inc. (LVTTF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Levitee Labs Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Modern Plant Based Foods Inc. (MDRNF) Income Statement Analysis – Financial Results
- Alpha Energy, Inc. (APHE) Income Statement Analysis – Financial Results
- Whitehorse Gold Corp. (WHGDF) Income Statement Analysis – Financial Results
- Huhtamäki Oyj (0K9W.L) Income Statement Analysis – Financial Results
- Park Street A/S (PARKST-A.CO) Income Statement Analysis – Financial Results
Levitee Labs Inc. (LVTTF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.leviteelabs.com
About Levitee Labs Inc.
Levitee Labs Inc., a multidisciplinary integrative wellness company, provides evidence-based alternative medicines and novel psychedelic therapies. The company operates through two segments, Medical Services and Selling Products. It offers treatments and medications for substance use disorders and chronic pain, such as myofascial pain, fibromyalgia, neuropathy, and chronic regional pain syndrome, as well as hepatitis-C and mental health conditions. The company operates five clinics under the Levitee Clinics name; and three pharmacies in Alberta under the Levitee Pharmacies name. In addition, it offers electronic-prescriptions in the addiction treatment space under the BlockMD name; and wholesales supplements and superfood under the Earth Circle Organics name. The company was formerly known as Fibonacci Capital Corp. and changed its name to Levitee Labs Inc. in November 30, 2020. Levitee Labs Inc. was incorporated in 2019 and is based in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 1.72M | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 1.03M | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 687.64K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 39.95% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 10.74M | 431.27K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 675.40K | 412.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 11.41M | 431.68K | 309.79K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 6.18K | 0.00 |
| Operating Expenses | 0.00 | 0.00 | 11.68M | 431.68K | 309.79K |
| Cost & Expenses | 0.00 | 0.00 | 12.72M | 431.68K | 309.79K |
| Interest Income | 0.00 | 0.00 | 34.34K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 46.05K | 245.00 | 518.00 |
| Depreciation & Amortization | 167.90K | 228.49K | 268.85K | -6.18K | 171.86K |
| EBITDA | 0.00 | 0.00 | -10.10M | -437.86K | -309.79K |
| EBITDA Ratio | 0.00% | 0.00% | -586.76% | 0.00% | 0.00% |
| Operating Income | 0.00 | 0.00 | -11.74M | -431.68K | -309.79K |
| Operating Income Ratio | 0.00% | 0.00% | -682.16% | 0.00% | 0.00% |
| Total Other Income/Expenses | 0.00 | 0.00 | -625.19K | 6.18K | -516.00 |
| Income Before Tax | 0.00 | 0.00 | -11.37M | -441.73K | -310.31K |
| Income Before Tax Ratio | 0.00% | 0.00% | -660.69% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 29.12K | 16.22K | 0.00 |
| Net Income | 0.00 | 0.00 | -11.40M | -441.73K | -310.31K |
| Net Income Ratio | 0.00% | 0.00% | -662.39% | 0.00% | 0.00% |
| EPS | 0.00 | 0.00 | -0.27 | -0.01 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | -0.27 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 0.00 | 0.00 | 41.47M | 80.11M | 80.11M |
| Weighted Avg Shares Out (Dil) | 0.00 | 0.00 | 42.13M | 80.11M | 80.11M |
Levitee Labs announces completion of Earth Circle sale; amends financing terms with RiverFort Global Opportunities
Levitee Labs appoints economist David Bentil as chief executive officer
Levitee Labs appoints Philip van den Berg as its new interim CEO; closes first tranche of its private placement
Levitee Labs announces non-brokered private placement of up to C$3M
Levitee Labs inks retail distribution agreement with Body Energy Club for MONKE Nutraceuticals
Levitee Labs Teams Up With Canntab Therapeutics, Offer Cannabinoid Products As Alternatives To Opioids
Levitee Labs partners with Canntab Therapeutics to provide alternative to drugs amid opioid crisis in Canada
Levitee Labs forms medical advisory board and welcomes six new members
Levitee Labs looking to be world's first listed psychedelic company with significant revenue and cashflow
Levitee Labs collaborates with LiveRx Research to test, treat and cure Hepatitis C; provide equitable access throughout Alberta, Canada
Source: https://incomestatements.info
Category: Stock Reports